Home Companies Climb Bio COMPANY
Clinical Phase 2
7 open jobs · last seen Oct 23, 2026 · 7 sources
Keywords: antibody immunology monoclonal antibody Primary Membranous Nephropathy Systemic Lupus Erthematosus Immune Thrombocytopenia ITP Biologics Anti-CD19 Systemic Lupus Erythematosus budoprutug CLYM116 Show all 12 keywords
Location: Wellesley Hills, MA · source · Oct 14, 2026
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Associate Director/Director, Program Manager, CLYM116 Wellesley Hills, Massachusetts Not stated Oct 17, 2026 Director, Legal Operations & Contracts Wellesley Hills, Massachusetts Not stated Oct 15, 2026 Sr. Director/Executive Director, Program Leader Wellesley Hills, Massachusetts Not stated Oct 14, 2026 Sr. Medical Director Wellesley Hills, Massachusetts Not stated Oct 11, 2026 Associate Director/Director, Clinical Drug Supply Wellesley Hills, Massachusetts Not stated Oct 11, 2026
See all 7 jobs
At a glance HQ Wellesley Hills, MA source Stage Clinical Phase 2 Latest trial 1: A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) (Jun 30, 2026) source Timeline Jun 30, 2026 Trial start 1: A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) source ↗ Apr 28, 2026 Raise Private placement: $110M (total, as published), announced Apr 28, 2026. Source: SEC filing. source ↗ · Form D filed May 4, 2026 SEC Form D ↗ Dec 2, 2025 Trial start 1: A Phase 1 Study of CLYM116 in Normal Healthy Volunteers source ↗ Aug 25, 2025 Trial start 2: A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy source ↗ Aug 11, 2025 Trial start 1: A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers source ↗ Jul 10, 2025 Trial start 1: A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) source ↗ Jun 30, 2025 Trial start 1: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) source ↗ Upcoming milestones 2027-04 (ESTIMATED) · 1 · A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) · NCT07011043 2027-08 (ESTIMATED) · 1 · A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) · NCT07043946 2027-09 (ESTIMATED) · 1 · A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) · NCT07564596 2027-10 (ESTIMATED) · 2 · A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy · NCT07096843 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $110.0M. Last 2 years.
Apr 28, 2026 Private placement: $110M (total, as published), announced Apr 28, 2026. Source: SEC filing. source ↗ · Form D filed May 4, 2026 SEC Form D ↗ Clinical trials (lead sponsor) 6 Record Title Phase Status Start Primary completion NCT07096843 A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy 2 Recruiting Aug 25, 2025 2027-10 (estimated) NCT07564596 A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) 1 Recruiting Jun 30, 2026 2027-09 (estimated) NCT07090655 A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers 1 Completed Aug 11, 2025 Apr 7, 2026 (actual) NCT07043946 A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) 1 Recruiting Jun 30, 2025 2027-08 (estimated) NCT07011043 A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) 1 Recruiting Jul 10, 2025 2027-04 (estimated) NCT07248865 A Phase 1 Study of CLYM116 in Normal Healthy Volunteers 1 Recruiting Dec 2, 2025 2026-07 (estimated)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
2026-05-04 Raise Private raise (SEC Form D): $110.1M sold; issuer “Climb Bio, Inc.”. Verified from the SEC filing. SEC filing ↗ Open jobs 7 Title Location (from posting, not HQ) Employer posted First seen Level Associate Director/Director, Program Manager, CLYM116 Wellesley Hills, Massachusetts Not stated Oct 17, 2026 Not stated Director, Legal Operations & Contracts Wellesley Hills, Massachusetts Not stated Oct 15, 2026 Senior Description Sr. Director/Executive Director, Program Leader Wellesley Hills, Massachusetts Not stated Oct 14, 2026 Executive Description Sr. Medical Director Wellesley Hills, Massachusetts Not stated Oct 11, 2026 Senior Description Associate Director/Director, Clinical Drug Supply Wellesley Hills, Massachusetts Not stated Oct 11, 2026 Senior Description Senior Clinical Trial Manager Wellesley Hills, Massachusetts Not stated Oct 11, 2026 Senior Description Associate Director/Director, Data Management Wellesley Hills, Massachusetts Not stated Oct 11, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Climb Bio on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
